Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden
- PMID: 37038743
- DOI: 10.1176/appi.ajp.20220649
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden
Keywords: Cognition/Learning/Memory; Pharmacotherapy; Schizophrenia Spectrum and Other Psychotic Disorders.
Conflict of interest statement
Dr. Light has served as a consultant for Astellas, Johnson & Johnson, Neurocrine, NeuroSig, Novartis, and Sosei-Heptares Therapeutic. Dr. Nuechterlein has received research grants from Janssen Scientific Affairs that support other research, and has been a consultant to Astellas, Janssen, and ReCognify. All other authors report no financial relationships with commercial interests.
Comment in
-
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh.Am J Psychiatry. 2023 Nov 1;180(11):841-842. doi: 10.1176/appi.ajp.20230419r. Am J Psychiatry. 2023. PMID: 37908092 No abstract available.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical